The human dopaminergic system is key to treating Parkinson's disease and schizophrenia. Recent studies confirm the safety of hESC?derived mDA progenitors and clarify synaptic vesicle pools involved in dopaminergic signaling. The company offers a Dopaminergic Neuron Differentiation Service using dual?SMAD inhibition and floor?plate induction to generate high?quality mDA neurons and 3D organoids. The service provides mature, physiologically relevant cells with reliable electrophysiological function, supporting disease modeling, drug screening, and regenerative medicine with high consistency and clinical translatability.
